0000849146-14-000039.txt : 20140624 0000849146-14-000039.hdr.sgml : 20140624 20140616091230 ACCESSION NUMBER: 0000849146-14-000039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20140616 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140616 DATE AS OF CHANGE: 20140616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 14921855 BUSINESS ADDRESS: STREET 1: 9815 S. MONROE STREET STREET 2: SUITE 100 CITY: SANDY STATE: UT ZIP: 84070 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 9815 S. MONROE STREET STREET 2: SUITE 100 CITY: SANDY STATE: UT ZIP: 84070 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 form8-k12june2014.htm 8-K Form 8-K 12June2014



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2014
 ______________________________
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________ 
Colorado
 
001-35647
 
90-0224471
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
9785 S. Monroe Street, Suite 300, Sandy, UT
 
84070
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
 
 
 
Registrant’s telephone number, including area code: (801) 432-9000
______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 8.01
Other Events
On June 16, 2014, LifeVantage Corporation (the "Company") issued a press release announcing changes in its Japan operations. A copy of the press release is attached as Exhibit 99.1 to this report.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibit Number
 
Description
99.1
 
Press release issued by the Company on June 16, 2014






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 16, 2014
LIFEVANTAGE CORPORATION
  
By: /s/ Rob Cutler   
Name: Rob Cutler
Title: General Counsel



EX-99.1 2 pressreleasejapanfinal.htm PRESS RELEASE PressReleaseJapanFINAL


LIFEVANTAGE ANNOUNCES CHANGES IN ITS JAPAN OPERATIONS
SALT LAKE CITY, UT, June 16, 2014 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, today announced that it has appointed Jeffery Bean as its new Managing Director in Japan. Mr. Bean brings 15 years of network marketing experience to LifeVantage, having worked in management positions for companies such as VISI, Stemtech International, LIV International, Synergy Worldwide and Neways, Inc. during his career. Mr. Bean will be based in the Company’s Tokyo office.
Douglas C. Robinson, the Company’s President and Chief Executive Officer said, “Our Japan market is very important to our overall business. We are excited to have Jeff join our team in Japan and we believe he will add a great amount of stability and value to our Japan market. Jeff brings a wealth of experience in the network marketing industry, particularly in Japan.”
In addition, the Company announced that it is working on a financial arrangement with two of its top distributor leaders in Japan who are no longer participating in the Company’s distributor activities. The Company believes this arrangement will promote greater unity among its other distributor leaders in Japan.
About LifeVantage Corporation
LifeVantage Corporation (LFVN), a leader in Nrf2 science and the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, TrueScience Anti-Aging skin care regimen with enhanced Nrf2 technologies, and Canine Health, is a science-based network marketing company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, Utah.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism and satisfaction with current prospects, as well as words such as “believe,” “anticipates,” “look forward to,” “should” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements




we make regarding how appointing a new managing director in Japan will affect our business in Japan and whether we will reach a mutual agreement with our distributor leaders and whether such an agreement will indeed promote the expected unity in that market. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others the risk factors discussed in greater detail in the Company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
Investor Relations Contact:
Cindy England (801) 432-9036
Director of Investor Relations
-or-
John Mills (310) 954-1105
Partner, ICR, INC


GRAPHIC 3 lifevantagelogojpega02.jpg begin 644 lifevantagelogojpega02.jpg M_]C_X``02D9)1@`!`0$`E@"6``#_X0!:17AI9@``34T`*@````@`!0,!``4` M```!````2@,#``$````!`````%$0``$````!`0```%$1``0````!```7$5$2 M``0````!```7$0```````8:@``"QC__;`$,`"`8&!P8%"`<'!PD)"`H,%`T, M"PL,&1(3#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T M,O_;`$,!"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(`$\!]P,!(@`"$0$#$0'_ MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0# M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$! M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<` M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z***` M$)`&2<`5E:Q<&;2KJ*UD83,AVE>/PS5G4'(1$'0\FL^MJ4=I'/6G=.!Q_A?7 M#I>JB&>1OLL_RL">%;L?Z&O0_M\/^U^5>>^)M#92]]:H6C/,J*/NGU'M5KPS MX@2]C6QNI`+I!A&)_P!8/\:ZZ].-3]XCAPM2=']U+Y'-%2=D='/%% MOXA^T1+"T%S;XWQDY!!Z$&NRLG+VXSS@XJ*M+D-*5;G+-9-WXCTVRNGMIY76 M1/O`(3VS6M7FOB;_`)&*[^J_^@BM,)1C5FXR[&&/Q,\/34H=ST2TNHKVUCN( M"3&XRI(Q4U97AO\`Y%ZS_P!T_P`S6K6%2*C-Q70ZJ4G.G&3ZI!1114&@445! M>7"VEG-<,,B)"V/7`II-NR$VDKLBOM5LM-4&ZG5">B]6/X"H-.U^PU2=H;9G M\Q5W89".*\ZDDN=2OB[;I;B9N!ZD]`/:NO\`#F@7NEZ@;BX\K:T17"MD@Y%= M]7"TZ5/WG[QY-''5J]:T(^Z=31117GGKA1110`5FWWB#2-,NTM+[4;>WN'`* MQRN%)!.!^M:5>=_%SP__`&CX>3584S<6!R^!R8CU_(X/YUI2C&EZSYG]FWT%UY6-_E-NVYZ9_(UQ MWQ:\0?V7X:&FPOBXU`E#CJ(Q][\^!^)K5^'GA_\`X1_PG;QR)MNKG]_/QR"1 MP/P&!]U;K>SCLEJ=71116)N%%%%`!1110`4444`%%%%`!7( M>._&-O_`-L?XU1J]J/6/\` M&LRYN8+.V>XN95BA099V/`KII_"CDJ_$R6N:UGP?;7K&>SE%G(&RP'N1U_$"KC>1XWT>.\L MRUM-&QC:*<A!]QGK6MX?S']J@ M;[R.,_J/Z4G[J;M9HI6G97NF5?"WA4>'Y+JYEG6:YN,*=@(55'8>M=O8?\>Y M_P!ZLRM.P_X]S_O5R5I.2NSMH1479%JO-?$W_(Q7?U7_`-!%>E5YKXF_Y&*[ M^J_^@BMLO_BOT.7-_P""O7]&=KX;_P"1>L_]T_S-:M97AO\`Y%ZS_P!T_P`S M6K7)6_B2]6=^'_@P]%^05A>+G>/0F9'9&\Q>5.#UK=JIJ-[;:?:&>ZSY08#A M<\GVHI-JHFE<,1%2I23=M-SC_!T\TFLNKS2./))PS$]Q6YXHU.WMM/ELI-_G M7$9V87CKW-6M-UO3M1N3#:;O,"ECF/;Q61XQTZYN#'=QHIA@C/F$M@CGTKLN MJF)3FN4\_E=+!R5*7-_6IS.CW<5CJUO MZ')EE2LI*$5[K>NGD=16#J/BRPLG:*+=TK.R.O$XZHZGL<.KLU&\< M7.[Y;*(+Z%SFKUEXTM96"7<#P9_C!W+_`(T]?!.G!,/-OO6B6#J/E6AC)YA27.]5\CNXI4FC62)U=&&593D&DG@ MCN;>2"9`\4JE'4]"",$5Y]X(H2HRL>E MA,5'$POUZH\7\&SR>"?B1=^'KIR+6Z?RD+=">L;?B#C\:]HKRWXP:$YMK3Q# M:@K-:L(IF7J%)RK?@W'XUW'A/7$\1>&K/401YCIMF`_AD'#?KS]"*TK_`+R$ M:J]'ZD8;]W.5%]-5Z&U1G`R:*X[XE>(/["\)S+$^VZO/W$6.H!'S-^`_4BN: M$'.2BNIU5)J$7)]#A8,_$/XKM*?GTRR.1Z&-#Q_WTW/T->UUPGPJ\/\`]D>% MEO)4QUJJG#9:')1DJ-%U:F[U_P`D;'B/XCZ%X=E>W:1KN\7AH;?!VG_:;H/Y MUR1^,&JW!+V?AHO".^]VX^H7%;G@_P"&6GZ1;QW>KQ)>ZDPW,L@W1Q'T`Z$^ MY_"N_5510J*%4<``8`J7*A#1+F\RE'$5-7+E\CS'3/C-82S"'5M-GLSG!>-O M,`^HP"/UKH]%^(&EZ]XCDT>QBF_I6KK?AC2/$-NT6HV4< MC$?+*!B1?HW6O*_`.FIHWQ8O=-CD:1+:.:-788)`(ZU:C1J0E**LTB)2KTIQ MC)W39[6>!FN*TOXGZ#?PWLUP9+&.T*@FX(RY.>%`))/%=HWW3]*\!^'WA"U\ M4Z[>/?L3:69#-$IP9"Q.!GL.#FLZ%.$H2E/I8TQ%6I"<(T^MSL[KXQV;3&+2 M=&O+UAT).S/X`$U7_P"%LZM!^\N_"-S'#W;(# M`6)`HJU2]I16T/Q'[*N]74_!''^'/B1H/B*9+99'M+Q^%AN,#!;"_T>YU>PMTM]0MD,S&(;1*HY(('?'(-:?PUU^?7_``G&]VY>YMG, M$CGJ^`""??!'Y45*<'#VE/;J@IU9JI[*IOT?<9XH^(VG>%=6&G75G=2R&(2; MHMN,'/J?:O,_'_CFQ\7P6,=G:W$)MG=F,NWG('3!/I7NEQIFGW*2U,,9&K[.3S MF^6G'7U.B'M*:YJDM/0MZ_XHTCPU;B74[H1LP^2)1ND?Z+_7I7`3_&62>8II M6@2SJ#UDD.3_`,!4''YU4\'^";CQ?<-XE\42R31SMNBA)P91ZGT3T`_EU];M M+*UL(%@L[:*WB48"1(%'Z5ZUS/\#.+KUO>3Y5^)Y=!\998)@FJ^'Y85 M)ZI(0P_!@,_G6WN.>]725"K*W+9D5GB M*,>;FNO0]YHH[5YU\2_&-QIB1:#I#-_:5V!O:/[T:DX`7_:8_E^5')'MY)6NKQ>#!;X)4_[1Z#^?M7(_\`"X-3N"7L_#+/ M#V.]F_4+BMKP=\,;#28([S68DO-28;BLGS1Q'T`_B/N?PKT!45%"HH51P`!@ M"MW*A#1+F\SG4<14]YRY?(\QTSXS6,DXAU;3)[,YP7C;S`OU&`1^M=%H_P`0 M=+USQ*^C6,4 M^!]+31?B[H!X`[G].>E M2=1]DMSIK5E36UV]D;^M?%_1;"9H-.@EU&0'&]#LCS[$\G\!6/\`\+>UA1YK M^&&$/KN<YE`:1C]>WT%=#6KJ4(Z*-_5F2I MXB6LIV\DC@]!^*^A:O*MO=A].G8X'G$&,G_>'3\<5W8(8`@@@\@BN3\4?#[1 MO$=O(ZP):7V/DN(EQD_[0'WA^M\0-X.UXG`;9;.QSL;J%![JPZ M?_7H=.%2+E2W704:M2G)0JZI[/\`S/6J***Y3L"BB@G`R>E`&5K=S#9V_P!H MN'"11J2S'_/6O*;^XU/QGJHM[9"L"'*H3\L8_O,?7_(K;\1ZC<>+-;33;`YM M(6.&['U<^WI_]>NAL[2R\/Z<(D#+&.9)-A)8^IQ7H4X^SBNYYM62J2=G[I2T M/PAIFBA9?*6YO.\\JYP?]D=OYULWA_T*X)/2)OY4EM>6UXI:VN(Y0.NULD?A M1>_\>%S_`-5^D=TNT_[P_S^ MM<)X-_Y'H_\`7K)_-:]&OK47=L8P=L@.Y&]&'2MJKM/7L84%>GIW+-:=A_Q[ MG_>K)A,C0H9E"R$?,`<\UK6'_'N?]ZN.KL=U'XBU7FOB;_D8KOZK_P"@BO2J M\U\3?\C%=_5?_016^7_Q7Z')F_\`!7K^C.U\-_\`(O6?^Z?YFM6LKPW_`,B] M9_[I_F:U:Y*W\27JSOP_\&'HOR"L#QA_R`&_ZZ)_.M^L#QA_R`&_ZZ)_.JP_ M\6/J1C/]WGZ,P/!?_(:D_P"N)_F*ZOQ#_P`B_>_]"_^0U)_UQ/\Q75^ M(?\`D7[W_KF:ZL5_O*^1PX+_`'*7S_(X?PW_`,C#9_[Q_D:]*8A5+'H!DUYK MX;_Y&&S_`-X_R->E,NY&4]QBEF'\1>@\H_@R]?T1Y+<3&YNY)I"TMH[>**Y6.-=H'EC_&N+EB,-P\4@(*.5;UX-=;#X+M9X4ECU"1D=0R MD(.0:[,2J/*O:/0\[!/$T5E@=MRJPP1GM7H^A7#76B6DK'+&/:3[CC^E8?_``@T'_/]+_WP*Z'3;%=- MT^*T5RXCS\Q&"?P%>Q5Y%\5]*FTO6=/\56 M&4D#JDC#M(O*$_4`C\!6.&:E>D^OYG7BDXVK+[/Y'KM>*^(';Q]\4H-)B8M8 M6;&-B#QM4YD;\3\OY5W6N>,X+?X>?V]:L!)=1!+=<])6XQ_P$Y_[YK%^$&@& MTT>?6YU/GWK;8RW7RP>OXMG\A3HITH2J/?9>I-=JM.-);;OT/2$18XU1%"HH M`4#H!7CW@J,>(_BMJVK7'SBU:1XP><'=L3\ES7L=>/?#I_[(^).MZ5<';)*9 M%3/1>&O\`DN.L?]MO_9:Z2_!G_C_`->^L?\`-Z*7\&I\OS"M_'I_/\CUNBBBN8ZS.U__`)%S4_\` MKTE_]`-<)\%?^1;U#_K[_P#9%KN]?_Y%S4_^O27_`-`-<)\%?^1;U#_K[_\` M9%KIA_N\O5')4_WF'HSTRO*?C;_QYZ-_UUE_DM>K5Y3\;?\`CST;_KK+_):, M)_&B/&_P)?UU/3[/_CQM_P#KFO\`*O)_B>7UGQSH>@!B(CLR/>1\$_D*]8L_ M^/&W_P"N:_RKR?XBL=(^)>A:O)_J,1DG_<<[OT(IX7^+YZDXS^#Y75SUR&&. MW@C@A0)%&H1%'0`#`%/I`0RAE(((R".]+7*=@5Y'\8?^0UX?^K?^A+7KE>1_ M&'_D->'_`*M_Z$M=.$_C+Y_DN=J\=\(1CQ'\7-5U2X^=;1I'C# M1G$D=NVP^C'@'\S7GOPJU'0-$T2ZN+_`%2SM[VY MFP5EE`8(HXZ^Y)KO?&]H]]X*U>",$N;=F`'?;\W]*\S^'G@KP]XJT.:>]^T? M;()BCB.7:-I`*G&/K^5:4>3V$N;N9UW/ZQ'E73J>G?\`":^&/^@]I_\`W_6C M_A-?#'_0>T__`+_K7/\`_"H/"W]V]_[_`/\`]:C_`(5!X6_NWO\`W_\`_K5G MRX?NS7FQ/9'0?\)KX8_Z#VG_`/?]:\R^*FH:/?7.F:MH^I6T]["Q1_(D#,`/ MF4\>AS^==;_PJ#PM_=O?^_\`_P#6H_X5!X6_NWO_`($?_6K2E*A3ES)LRK0Q M%6#@TCL]-NOMVEVEWT\^%)/^^@#_`%HI]G:QV-E!:0Y\J"-8TW')P!@45QNU M]#N5[:D]EQ[ M@#=2\S-Z'LH]A5VMMT61"K#(-5#IRYXD('N*:JWUD#H\ND=CC-<\.M+F_P!) M8V]^GS`1G:)/\#_.J&B>,$U:VNM-OP(=22)\#&!+@'.!V8=Q7H/]G#_GJ?\` MOFO+?B3X5:QU6QURSSLFG6.XVC&U\\-^/0__`%ZZ*52-1\C?HG.G%SBO4 MI^#?^1Z/_7K)_-:]/KS7P/%YWC\INQ_HDAZ>ZUZS_9P_YZG_`+YHQ$TIV8\+ M"3A=%"M2P!%MD]SD4Q-/0'+.6'IC%6P`H``P!TKDG--61VTZ;3NQ:\U\3?\` M(Q7?U7_T$5Z57+:KX4FU'4YKM;M$60C"E"<8`%;X*I&G4;D[:'+F5&I6I*-- M7=RII/BNTT_2X+62WF9XQ@E<8//UJ[_PF]E_SZW'_CO^-4?^$'N/^?Z+_OV? M\:/^$'N/^?Z+_OV?\:Z)+!R;;?YG'!YC&*BHZ+T-:Q\5VE_>Q6L=O,K2'`+8 MP./K1XP_Y`#?]=$_G532_"FOJNFFUCD6-BX; MAUQ6(J8:<:J]YWL(JPE74HO306$HU( M85PDM=3S[PW_`,C#9_[Q_D:]+KE-+\)W&GZG!=/=1.L9)*A3D\8KJZ6-J1J3 M3B[Z#RVC4I4FJBL[G$^+=&>.=M2@3,3_`.N`_A/K]#5'1/$DVE+Y$J&:USD* M#\R?3_"O0R`RE6`((P0>]>W]?(V/#^L_P!K MV9+QE9HL!R!\I]Q_A6O45O;0VD"PV\:QQKT514M>?4<7)N*LCUZ49Q@E-W85 ME^(M'BU_0+S3)<#SHR$8_P`+CE3^!Q6I14IM.Z+DE)69\RZ?::KJ^H67A-W= M5CNW'E$?ZICPY_`*3^?K7TI:6L-C9PVEN@2&%!&BCL`,"L2S\)6EGXROO$28 M\RYB5`F/NM_&WX@+^OK70UTXFNJMK;?J'[W3=6@\8 MZ.")82IN-HSM*]'QZ8X->K4C*KJ590RL,$$9!%8TJCIRYD;UJ2JPY6L7=Y;6% MJ]S=SQP01C+22-@"O'_!5];ZG\8=2OK5B]O.LSQL1C(R.<59C^&?BC7ITE\3 M:Z?+!SL60RL/H.%'ZUO>%_AR_AGQ9)J<-XCV7EM''$02X!QC)Z=JN*I4X27- M=M&M'D$5QG@7P5<^$KC49;B\ MAN!=[=HC4C;@MUS]:QISBJ4XO=V-ZL).M"2V5_R.THHHK`Z3.U__`)%S4_\` MKTE_]`-<)\%?^1;U#_K[_P#9%KT/4K5KW2[NT5@K3PO&&/0%@1G]:YWP'X3N M/".EW-I<74=PTLWF!HU(`&`,<_2MXSBJ,H]=#FG"3KQDMDF=77E/QM_X\]&_ MZZR_R6O5JX[Q]X-N?&$%C';W<5N;9W9C(I.[('I]*,-)0JJ4MAXJ$IT7&.YU M5G_QXV__`%S7^59=T>OUXI\4M:T_5/$FE6]C*N/X.^(NNCR=6UI8;<_>4S\'_@*#!_&IYO@R(OL1L=3'F1M MNG>9#\YR,;0.@Z^M:48TJ4N:4KOR,Z\JU:'+&%EYGK':O*_B;X>O++4K?Q?I M`836Y4W&P0?5?5?\FNGKS?Q#\);.\NC>Z%='3;G.[R\'R\^HQR MOX5E#0OBI9#R8-5$T8X#&X5OU<9K9TJ4]82MY,P5:M#2I"_FCU>ZNK>RMGN; MJ:.&&,9:21@`!]:\?\(7]OJGQGOKZT71+XD87^[G.W_>7MZCZU[5534M M,LM7L9+*_MTGMY!\R,/U'H?>N:C5Y&U)73W.NO1=1)Q=FMANE:O8:U8I>:=< MI/"XZJ>5/H1U!]C5VO)[WX4ZII=XUWX5UMX">D2= M2"ITW^?&/U`S6GL*F^&[!KK4;A4X^2('+R'T M4=ZJ^$/%,7BS1S?1VTMNR.8W1^1G_9;N*XO2OA+/29R8HW8[O8 MNW./8`?6O3;6UM[&UCMK6%(8(EVI&@P%%145*,;1=WW+I2K3ES25EVZE:YUO M3+.\%I-KY_(@TJWR9KE@6`],\#\3_`"KH-*L$TS3( M+1,?NU^8^K=S^=1ZI>7<%A9S7=U*L4$*%W=CP`*\H^&BRZ] MXZUKQ(Z%8?F"Y_O.V0/P4?J*IIIOC?XC^6;^XBM=+W`G:P"?@@)+'_>KU?0= M"LO#FDQ:=8H1&G+,WWG8]6/N:V:C1@XWO)_@<\7+$5(RM:*_%FG1117(=H44 -44`%%%%`!1110!__V3\_ ` end